References

GENERAL INFORMATION

ACADEMIC REFERENCES

DEPRESSION

The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder.

Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4-6 weeks (20-30 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. In 2011, leading TMS clinical providers and researchers created the Clinical TMS Society (cTMSs) (www.clinicaltmssociety.org, Greenwich, CT, USA), incorporated…

Read more

Leuchter AF, Cook IA, Feifel D, Goethe JW, Husain M, Carpenter LL, Thase ME, Krystal AD, Philip NS, Bhati MT, Burke WJ, Howland RH, Sheline YI, Aaronson ST, Iosifescu DV, O’Reardon JP, Gilmer WS, Jain R, Burgoyne KS, Phillips B, Manberg PJ, Massaro J, Hunter AM, Lisanby SH, George MS. Efficacy and Safety of Low-field Synchronized Transcranial Magnetic Stimulation (sTMS) for Treatment of Major Depression. Brain Stimulation 8 (2015) 787-794

Read more

Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Major Depression: A prospective multicenter randomized controlled trial

Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial   Abstract: Major depressive disorder (MDD) is a prevalent and disabling condition, and many patients do not respond to available treatments. Deep transcranial magnetic stimulation (dTMS) is a new technology allowing non-surgical stimulation of relatively deep brain areas.…

Read more

A multisite, naturalistic, observational study of transcranial magnetic stimulation for patients with pharmacoresistant major depressive disorder: durability of benefit over a 1-year follow-up period

Abstract: Transcranial magnetic stimulation (TMS) is an effective and safe acute treatment for patients not benefiting from antidepressant pharmacotherapy. Few studies have examined its longer term durability. This study assessed the long-term effectiveness of TMS in naturalistic clinical practice settings following acute treatment. Adult patients with a primary diagnosis of unipolar, nonpsychotic major depressive disorder…

Read more

Transcranial Magnetic Stimulation (TMS) for Major Depression: A Multisite, Naturalistic, Observational Study of Acute Treatment Outcomes in Clinical Practice

Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice   Abstract: Few studies have examined the effectiveness of transcranial magnetic stimulation (TMS) in real-world clinical practice settings. Forty-two US-based clinical TMS practice sites treated 307 outpatients with Major Depressive Disorder (MDD), and persistent symptoms despite…

Read more

H-Coil Repetitive Transcranial Magnetic Stimulation for Treatment Resistant Major Depressive Disorder

H-Coil repetitive transcranial magnetic stimulation for treatment resistant major depressive disorder: An 18-week continuation safety and feasibility study   Abstract: Evidence has shown that repetitive transcranial magnetic stimulation (rTMS) can be effective as an acute treatment for major depressive disorder (MDD). However, few studies have examined the safety and feasibility of rTMS as a long-term\continuation…

Read more

Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial.

Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial.   Abstract: We tested whether transcranial magnetic stimulation (TMS) over the left dorsolateral prefrontal cortex (DLPFC) is effective and safe in the acute treatment of major depression. In a double-blind, multisite study, 301 medication-free patients with…

Read more

OCD

PTSD

METH ADDICTION

TMS GUIDELINES & CONSENSUS RECOMMENDATIONS

Insurance Coverage for TMS

Within California, Oregon, and Alaska, Transcranial Magnetic Stimulation has been approved for use with treatment resistant depression by several insurance providers. Insurances that we’re in network with include Cigna, Anthem Blue Cross, Magellan, Tricare, Blue Shield of CA, Blue Shield Federal Employee, Optum, Aetna, MHN, Healthnet, Beacon, Prime Health Services, Provider Select, Medicare, Providence Preferred, Providence Health Plan, Regence Blue Cross Blue Shield, First Choice Health Network, First Health National Network, Pacificsource, Moda, OHA (fee for service only), First Health, and Premera Blue Cross. Please call us for a full list of providers. We would be happy to help check with your insurance regarding pre-approval.

*Unfortunately, Medi-cal currently does not cover TMS treatment in California. Please contact your Medi-cal provider to inquire further.

APA

CTS